Aerie Pharmaceuticals (United States)

Recent papers from Aerie Pharmaceuticals (United States)

1. Consensus Recommendations for Studies of Outflow Facility and Intraocular Pressure Regulation Using Ex Vivo Perfusion ApproachesInvestigative Ophthalmology & Visual Science · 2024
2. Relationship between Retinal Oxygen Saturation and the Severity of Visual Field Damage in GlaucomaJournal of Glaucoma · 2024
3. Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET)Advances in Therapy · 2023
4. Rho Kinase Inhibitor AR-12286 Reverses Steroid-Induced Changes in Intraocular Pressure, Effective Filtration Areas, and Morphology in Mouse EyesInvestigative Ophthalmology & Visual Science · 2023
5. Discovery and Preclinical Development of Novel Intraocular Pressure-Lowering Rho Kinase Inhibitor: Corticosteroid ConjugatesJournal of Ocular Pharmacology and Therapeutics · 2023
6. A randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1)The Ocular Surface · 2022
7. Effects of Netarsudil-Family Rho Kinase Inhibitors on Human Trabecular Meshwork Cell Contractility and Actin Remodeling Using a Bioengineered ECM HydrogelFrontiers in Ophthalmology · 2022
8. Effects of netarsudil-family Rho kinase inhibitors on human trabecular meshwork cell contractility and actin remodeling using a bioengineered ECM hydrogel2022
9. Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasiseLife · 2021
10. A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world settingCurrent Medical Research and Opinion · 2021
11. Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular HypertensionAdvances in Therapy · 2021
12. Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 StudyAmerican Journal of Ophthalmology · 2021
13. A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle GlaucomaOphthalmology and Therapy · 2020
14. Effects of Netarsudil on Actin-Driven Cellular Functions in Normal and Glaucomatous Trabecular Meshwork Cells: A Live Imaging StudyJournal of Clinical Medicine · 2020
15. Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular HypertensionJournal of Glaucoma · 2020
16. Antifibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis2020
17. One Year of Netarsudil and Latanoprost Fixed-Dose Combination for Elevated Intraocular PressureOphthalmology Glaucoma · 2020
18. Effects of Netarsudil on the Corneal EndotheliumOphthalmology Glaucoma · 2020
19. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2Advances in Therapy · 2020
20. Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2Advances in Therapy · 2020